Business Wire

IL-ZS

28.7.2021 15:02:04 CEST | Business Wire | Press release

Share
ZS Elects Pratap Khedkar to CEO

Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/

Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about.

Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global pharmaceuticals and biotechnology practice for nearly a decade, driving growth and market penetration across both established and emerging companies. While heading up the firm’s advanced data science track, he and 250 data scientists helped integrate AI-enabled solutions across many business areas. He’s recently turned his attention to expanding the firm’s healthcare expertise to help clients establish deeper relationships and more effective partnerships across the healthcare ecosystem to improve health outcomes, emphasize a better patient experience and address health disparities.

“Pratap is stepping into this role during an exciting period of growth and change at ZS,” said Wright, who oversaw the company’s 30% growth in 2020. “We’re increasingly being called in by the companies we partner with to identify, advise on and adapt to the next big shifts in their respective industries. I’m confident that under Pratap’s counsel, the best days at ZS are ahead of us.”

“Chris has done a tremendous job during his tenure as CEO, and I’ll be leaning on his knowledge and guidance in the months and years ahead,” Khedkar said. “His greatest legacy is preserving the culture that our founders worked so hard to create. His emphasis on continually investing in our people has ‘kept the magic alive,’ as he’s been known to say.”

Khedkar will oversee the global acceleration and scaling of ZS’s portfolio of life sciences and healthcare work. He plans to ramp up investments in the firm’s technology, digital analytics and software capabilities across healthcare and in other industries. To continue working alongside clients and staying connected to market trends, Khedkar is making a critical adjustment to the leadership operating model by appointing 20-year ZS veteran Sandra Forero to the firm’s newly created chief operating officer role.

Forero has held various leadership positions at ZS, including client service lead for two major biopharma clients, head of the firm’s integrated analytics practice, founding chair of the people and culture team, chair of the inclusion and diversity council and elected member of ZS’s shareholder’s council since 2015.

“I welcome Sandra to this role and look forward to partnering with her. She’s a trusted and respected leader at ZS who is incredibly passionate about driving client impact, ensuring the growth and success of our people and stewarding our culture,” Khedkar said. “Our commitment to excellence and solving complex problems is critical for both personal and firm growth and has made ZS what it is today. And, we’re strongly positioned to continue doing more of what ZS does best: helping companies and their customers thrive.”

“At ZS, we work together to leverage our deep expertise in industry and functional areas, analytics and technology to cultivate a culture of innovation and collaboration for client benefit,” said Jaideep Bajaj, chairman of the board at ZS. He held the position of CEO from 2003 to 2012. “I’m excited about ZS’s next era with Pratap leading a strong team that’s focused on creating value for our clients.”

Khedkar holds a Ph.D. in artificial intelligence from the University of California, Berkeley and a Bachelor of Technology degree in computer science from the Indian Institute of Technology Delhi.

About ZS

ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 10,000-plus ZSers in 28 offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye